Screening test for MRSA

Rapid detection of MRSA ensures timely intervention to reduce spread of the disease, resulting in fewer costly infections and better bed management.

The same system can be further developed to detect other problem bacteria where a rapid indicative screen would be desirable e.g. Clostridium difficile, Acinetobacter baumanii etc.

The patented new technology, phiteq, which drives the rapid screening system, is also being used to create a ward protection system. As an additive for decontamination products, this enables hospital surfaces to be cleaned as normal. However, it will continue to kill MRSA on contact for up to two weeks. Both sets of products are the result of a recent scientific breakthrough in the field of bacteriophages – nature’s antidote to bacteria.